CRP and hyperlipidemia: Those findings were further corroborated in the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), demonstrating that even in otherwise healthy subjects not diagnosed with hyperlipidemia but with elevated high-sensitive CRP, statins reduced the incidence of cardiovascular events, along with a substantial CRP decrease of 37% [30].